0.95
+0(+0.00%)
Currency In GBp
Address
Mailpoint 810
Southampton, SO16 6YD
United Kingdom of Great Britain and Northern Ireland
Phone
44 23 8051 2800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
36
First IPO Date
October 26, 2004
| Name | Title | Pay | Year Born |
| Mr. Richard Marsden | Chief Executive Officer, MD & Executive Director | 328,000 | 1967 |
| Prof. Stephen T. Holgate CBE, M.D. | Co-Founder & Member of Scientific Advisory Board | 40,000 | 1947 |
| Mr. Joseph Tregonning Colliver F.C.A. | Chief Financial Officer & Executive Director | 197,410 | 1980 |
| Dr. Marcin Mankowski M.D. | Chief Medical Officer | 0 | N/A |
| Prof. Ratko Djukanovic | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Prof. Donna Davies | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
| Mr. Richard Francis | Senior Vice President and Head of CMC & Quality | 0 | N/A |
| Dr. Gareth E. Walters Ph.D. | Chief Regulatory Officer | 0 | 1959 |
| Dr. Victoria Tear | Head of Laboratory | 0 | N/A |
| Ms. Jody Brookes | Senior Vice President & Head of Clinical Operations | 0 | N/A |
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.